U
Acro Biomedical Co., Ltd.
ACBM
$0.0007
-$0.1043-99.33%
E
Sell
4/27/2023Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D- on 4/27/2023 due to a decline in the volatility index.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D- on 4/27/2023 due to a decline in the volatility index.
D
Sell
4/10/2023Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D- from E+ on 4/10/2023 due to an increase in the total return index and volatility index.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D- from E+ on 4/10/2023 due to an increase in the total return index and volatility index.
E
Sell
3/24/2023Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D- on 3/24/2023 due to a decline in the total return index and volatility index.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D- on 3/24/2023 due to a decline in the total return index and volatility index.
D
Sell
3/14/2023Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 03/14/2023.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 02/09/2023.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 02/08/2023.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 02/08/2023.
D
Sell
1/12/2023Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 1/12/2023 due to an increase in the volatility index and total return index.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 1/12/2023 due to an increase in the volatility index and total return index.
D
Sell
10/17/2022Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 10/17/2022 due to a large decline in the growth index, total return index and solvency index. Operating cash flow declined 231.93% from $262.1 to -$345.8, the quick ratio declined from 9.94 to 3.81, and debt to equity increased from 0.07 to 0.08.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 10/17/2022 due to a large decline in the growth index, total return index and solvency index. Operating cash flow declined 231.93% from $262.1 to -$345.8, the quick ratio declined from 9.94 to 3.81, and debt to equity increased from 0.07 to 0.08.
D
Sell
5/16/2022Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 04/21/2022.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 04/20/2022.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 04/20/2022.
D
Sell
12/21/2021Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 12/21/2021 due to an increase in the total return index and volatility index.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 12/21/2021 due to an increase in the total return index and volatility index.
D
Sell
12/6/2021Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 12/6/2021 due to a large decline in the growth index and total return index. EBIT declined 276.99% from -$793.3 to -$2.99M, earnings per share declined from -$0.0157 to -$0.0526, and operating cash flow declined 114.9% from $432.8 to -$64.5.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 12/6/2021 due to a large decline in the growth index and total return index. EBIT declined 276.99% from -$793.3 to -$2.99M, earnings per share declined from -$0.0157 to -$0.0526, and operating cash flow declined 114.9% from $432.8 to -$64.5.
D
Sell
11/9/2021Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 11/08/2021.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D on 11/08/2021.
D
Sell
8/25/2021Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 8/25/2021 due to a large increase in the solvency index, growth index and volatility index. Operating cash flow increased 5,252.38% from -$8.4 to $432.8, the quick ratio increased from 0.08 to 3.58, and total revenue increased 402.51% from $99.5 to $500.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 8/25/2021 due to a large increase in the solvency index, growth index and volatility index. Operating cash flow increased 5,252.38% from -$8.4 to $432.8, the quick ratio increased from 0.08 to 3.58, and total revenue increased 402.51% from $99.5 to $500.
D
Sell
8/2/2021Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D- from E+ on 8/2/2021 due to an increase in the volatility index.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D- from E+ on 8/2/2021 due to an increase in the volatility index.
E
Sell
7/16/2021Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D- on 7/16/2021 due to a noticeable decline in the total return index and volatility index.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E+ from D- on 7/16/2021 due to a noticeable decline in the total return index and volatility index.
D
Sell
5/25/2021Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 5/25/2021 due to a significant decline in the efficiency index, growth index and solvency index. Debt to equity increased from 0.39 to 0.44, and total capital declined 5.09% from $953.3 to $904.8.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 5/25/2021 due to a significant decline in the efficiency index, growth index and solvency index. Debt to equity increased from 0.39 to 0.44, and total capital declined 5.09% from $953.3 to $904.8.
D
Sell
5/20/2020Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 5/20/2020 due to a major increase in the efficiency index and growth index. Total revenue increased 255.56% from $193.5 to $688, EBIT increased 208.22% from -$75.4 to $81.6, and net income increased 206.85% from -$75.9 to $81.1.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 5/20/2020 due to a major increase in the efficiency index and growth index. Total revenue increased 255.56% from $193.5 to $688, EBIT increased 208.22% from -$75.4 to $81.6, and net income increased 206.85% from -$75.9 to $81.1.
D
Sell
3/4/2020Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 3/4/2020 due to a decline in the volatility index and total return index.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D- from D on 3/4/2020 due to a decline in the volatility index and total return index.
D
Sell
1/8/2020Downgrade
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D from D+ on 1/8/2020 due to a significant decline in the efficiency index, volatility index and growth index. Net income declined 48.03% from -$50.8 to -$75.2, earnings per share declined from -$0.0011 to -$0.0016, and total capital declined 16.9% from $1.05M to $873.7.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to D from D+ on 1/8/2020 due to a significant decline in the efficiency index, volatility index and growth index. Net income declined 48.03% from -$50.8 to -$75.2, earnings per share declined from -$0.0011 to -$0.0016, and total capital declined 16.9% from $1.05M to $873.7.
D
Sell
11/5/2019Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D+ from D on 11/5/2019 due to an increase in the total return index.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D+ from D on 11/5/2019 due to an increase in the total return index.
D
Sell
5/1/2019Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 5/1/2019 due to an increase in the total return index and solvency index. The quick ratio increased from 0 to 0.36, and debt to equity declined from 0.11 to 0.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D from D- on 5/1/2019 due to an increase in the total return index and solvency index. The quick ratio increased from 0 to 0.36, and debt to equity declined from 0.11 to 0.
D
Sell
1/3/2019Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D- from E+ on 1/3/2019 due to a major increase in the growth index and efficiency index. Operating cash flow increased 99.18% from -$512.4 to -$4.2, total capital increased 50.72% from $917.8 to $1.38M, and earnings per share increased from $0.0024 to $0.0032.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to D- from E+ on 1/3/2019 due to a major increase in the growth index and efficiency index. Operating cash flow increased 99.18% from -$512.4 to -$4.2, total capital increased 50.72% from $917.8 to $1.38M, and earnings per share increased from $0.0024 to $0.0032.
E
Sell
10/1/2018Upgraded
Acro Biomedical Co., Ltd. (ACBM) was upgraded to E+ from E on 10/1/2018 due to a significant increase in the efficiency index, total return index and solvency index. Net income increased 67.34% from $69.5 to $116.3, and total capital increased 21.35% from $756.3 to $917.8.
Acro Biomedical Co., Ltd. (ACBM) was upgraded to E+ from E on 10/1/2018 due to a significant increase in the efficiency index, total return index and solvency index. Net income increased 67.34% from $69.5 to $116.3, and total capital increased 21.35% from $756.3 to $917.8.
E
Sell
7/6/2018None
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E from U on 07/06/2018.
Acro Biomedical Co., Ltd. (ACBM) was downgraded to E from U on 07/06/2018.
OTC PK
07/15/2024 9:30AM Eastern
Quotes delayed
